Factors contributing to the increasing placebo response in antidepressant trials

World Psychiatry

Volumn 14, Issue 3, 2015, Pages 304-306

  Kasper, Siegfried ^a   Dold, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; PLACEBO; VORTIOXETINE;

CLINICAL PRACTICE; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESPONSE; HUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SUICIDAL IDEATION;

EID: 84942520729     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20245     Document Type: Note

References (11)

1. Khan A, Brown WA., Antidepressants versus placebo in major depression: an overview. World Psychiatry 2015; 14: 294-300.
2. Walsh BT, Seidman SN, Sysko R, et al., Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840-7.
3. Adam D, Kasper S, Moller HJ, et al., Placebo-controlled trials in major depression are necessary and ethically justifiable: how to improve the communication between researchers and ethical committees. Eur Arch Psychiatry Clin Neurosci 2005; 255: 258-60.
4. Rutherford BR, Cooper TM, Persaud A, et al., Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout. J Clin Psychiatry 2013; 74: 703-15.
5. Rutherford BR, Roose SP., A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013; 170: 723-33.
6. Dunlop BW, Thase ME, Wun CC, et al., A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites. Neuropsychopharmacology 2012; 37: 2830-6.
7. Pae CU, Wang SM, Han C, et al., Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci 2015; 40: 174-86.
8. Leucht S, Hierl S, Kissling W, et al., Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012; 200: 97-106.
9. Montgomery SA, Rasmussen JGC, Tanghoj P., A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993; 8: 181-8.
10. Hegerl U, Mergl R., The clinical significance of antidepressant treatment effects cannot be derived from placebo-verum response differences. J Psychopharmacol 2010; 24: 445-8.
11. Huf W, Kalcher K, Pail G, et al., Meta-analysis: fact or fiction? How to interpret meta-analyses. World J Biol Psychiatry 2011; 12: 188-200.